Skip to main content

NPPA notify ceiling prices of four essential drugs and revised 14 more

 

Clinical courses

The NPPA drug price regulator has capped the prices of four essential drugs and revised 14 others, including those used for the treatment of fungal infections and hypertension.

NPPA has fixed/revised ceiling prices of 18 scheduled formulations of Schedule-I under Drugs (Price Control) Amendment Order,2016 under DPCO, 2013.

These are: Griseofulvin tablet, methyldopa tablet, human normal immunoglobulin, vitamin A tablet, calamine lotion, amphotericin B powder for injection - conventional, amphotericin B powder for injection - lipid/liposomal, acetylsalicylic acid tablet, verapamil injection, verapamil tablet, methyldopa tablet, vitamin A injection, furosemide tablet, furosemide injection, bupivacaine injection, lignocaine topical forms and verapamil tablet.

The concerned manufacturers of these formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS.

 

As stipulated under the Drugs (Prices Control) Order (DPCO) 2013, NPPA fixes ceiling price of essential medicines of Schedule I. In respect of medicines not under price control, manufacturers are allowed to increase the maximum retail price by 10 per cent annually

Manufacturers in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

If the retail price of one of the formulations is not complied with, according to the instant price notification and the specified notes, then the manufacturer / marketing company will be required to deposit the overcharged amount with interest on the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

Following the issuance of the retail price of the formulations indicated in this notification, any price order (s) issued for the relevant manufacturer / marketer prior to the said notification date have been replaced.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email